These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20607226)

  • 21. Understanding the role of innate immunity in the mechanism of action of the live attenuated Yellow Fever Vaccine 17D.
    Querec TD; Pulendran B
    Adv Exp Med Biol; 2007; 590():43-53. PubMed ID: 17191376
    [No Abstract]   [Full Text] [Related]  

  • 22. Characterization of Yellow Fever Virus Infection of Human and Non-human Primate Antigen Presenting Cells and Their Interaction with CD4+ T Cells.
    Cong Y; McArthur MA; Cohen M; Jahrling PB; Janosko KB; Josleyn N; Kang K; Zhang T; Holbrook MR
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004709. PubMed ID: 27191161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees.
    Mateus J; Grifoni A; Voic H; Angelo MA; Phillips E; Mallal S; Sidney J; Sette A; Weiskopf D
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33198381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection
    Douam F; Soto Albrecht YE; Hrebikova G; Sadimin E; Davidson C; Kotenko SV; Ploss A
    mBio; 2017 Aug; 8(4):. PubMed ID: 28811340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.
    Amanna IJ; Thomas A; Engelmann F; Hammarlund E; Raué HP; Bailey AL; Poore EA; Quintel BK; Lewis AD; Axthelm MK; Johnson AL; Colgin LMA; Diamond MS; Messaoudi I; Slifka MK
    Cell Rep Med; 2024 Jul; 5(7):101655. PubMed ID: 39019010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development.
    Franco D; Li W; Qing F; Stoyanov CT; Moran T; Rice CM; Ho DD
    Vaccine; 2010 Aug; 28(35):5676-85. PubMed ID: 20600494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A DNA vaccine against yellow fever virus: development and evaluation.
    Maciel M; Cruz Fda S; Cordeiro MT; da Motta MA; Cassemiro KM; Maia Rde C; de Figueiredo RC; Galler R; Freire Mda S; August JT; Marques ET; Dhalia R
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003693. PubMed ID: 25875109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.
    Sandberg JT; Ols S; Löfling M; Varnaitė R; Lindgren G; Nilsson O; Rombo L; Kalén M; Loré K; Blom K; Ljunggren HG
    J Immunol; 2021 Aug; 207(4):1033-1043. PubMed ID: 34321231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.
    Tretyakova I; Nickols B; Hidajat R; Jokinen J; Lukashevich IS; Pushko P
    Virology; 2014 Nov; 468-470():28-35. PubMed ID: 25129436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease.
    Barrett ADT
    Vaccine; 2017 Oct; 35(44):5951-5955. PubMed ID: 28366605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.
    Jiang X; Dalebout TJ; Bredenbeek PJ; Carrion R; Brasky K; Patterson J; Goicochea M; Bryant J; Salvato MS; Lukashevich IS
    Vaccine; 2011 Feb; 29(6):1248-57. PubMed ID: 21145373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface.
    Bonaldo MC; Garratt RC; Marchevsky RS; Coutinho ES; Jabor AV; Almeida LF; Yamamura AM; Duarte AS; Oliveira PJ; Lizeu JO; Camacho LA; Freire MS; Galler R
    J Virol; 2005 Jul; 79(13):8602-13. PubMed ID: 15956601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status and future prospects of yellow fever vaccines.
    Beck AS; Barrett AD
    Expert Rev Vaccines; 2015; 14(11):1479-92. PubMed ID: 26366673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.
    Liang H; Lee M; Jin X
    Cell Mol Immunol; 2016 Jan; 13(1):36-46. PubMed ID: 26435066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.
    Ma J; Yakass MB; Jansen S; Malengier-Devlies B; Van Looveren D; Sanchez-Felipe L; Vercruysse T; Weynand B; Javarappa MPA; Quaye O; Matthys P; Roskams T; Neyts J; Thibaut HJ; Dallmeier K
    EBioMedicine; 2022 Sep; 83():104240. PubMed ID: 36041265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limited replication of yellow fever 17DD and 17D-Dengue recombinant viruses in rhesus monkeys.
    Trindade GF; Marchevsky RS; Fillipis AM; Nogueira RM; Bonaldo MC; Acero PC; Caride E; Freire MS; Galler R
    An Acad Bras Cienc; 2008 Jun; 80(2):311-21. PubMed ID: 18506257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.
    Mantel N; Piras-Douce F; Chautard E; Marcos-Lopez E; Bodinham CL; Cosma A; Courtois V; Dhooge N; Gautheron S; Kaufmann SHE; Pizzoferro K; Lewis DJM; Martinon F; Pagnon A; Raynal F; Dereuddre-Bosquet N; Le Grand R
    J Virol; 2024 May; 98(5):e0151623. PubMed ID: 38567951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model.
    Tao D; Barba-Spaeth G; Rai U; Nussenzweig V; Rice CM; Nussenzweig RS
    J Exp Med; 2005 Jan; 201(2):201-9. PubMed ID: 15657290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice.
    Boudewijns R; Ma J; Neyts J; Dallmeier K
    JHEP Rep; 2021 Aug; 3(4):100295. PubMed ID: 34159304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.